Skip to main content
. Author manuscript; available in PMC: 2017 Jul 24.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2017 Jan 24;20(2):228–233. doi: 10.1038/pcan.2016.72

Table 4.

a. PHI by RP GG.
RP pathologic GG N (%) PHI (median, IQR)
1 (GS 6) 1 (3.3) 41
2 (GS 3+4=7) 16 (53.3) 32.9 (29.3–50.3)
3 (GS 4+3=7) 7 (23.3) 53.3 (50.4–115.2)
4–5 (GS 8-10) 6 (20.0) 67.6 (44.8–81.5)
b. PHI by RP stage.
RP pathologic stage N (%) PHI (median, IQR)
pT2N0 13 (43.3) 35.5 (29.8–49.3)
pT3aN0 13 (43.3) 50.4 (42.4–53.3)
pT3b/pTxN1 4 (13.3) 85.0 (72.6–108.1)

P=0.002 for GG≥3 vs. GG1-2

P=0.001 for pT3b/pTxN1 vs. ≤pT3aN0